CoChat

Editorial: Decernotinib: A Next‐Generation Jakinib

Open access
Gadina, Massimo, Schwartz, Daniella M., O'Shea, John J. · 2016 · Arthritis & Rheumatology
Cited by 40

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Since the beginning of this millennium, rheumatologists have become applied cytokine biologists, taking advantage of the plethora of successful “biologics” that target cytokines for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders. The mechanism of action of these agents is to block cytokines outside of the cell. However, the actions of cytokines can also be blocked by disrupting signaling pathways within the cell. This is the mechanism of action employed by a recent class of orally administered drugs, Janus kinase (JAK) inhibitors or Jakinibs. In this issue of A&R, Genovese and colleagues report the results of a Phase IIb study with decernotinib, a second generation, JAK3-selective Jakinib (1).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.39463

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 40

Metadata

Authors
Gadina, M., Schwartz, D. M., & O'Shea, J. J.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2015-12-23
Volume
68
Issue
1
Pages
31-34
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2272685247
Cited by
40
References
1
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Editorial: Decernotinib: A Next‐Generation Jakinib. https://app.cochat.ai/papers/10.1002/art.39463
The paper
Gadina, M., Schwartz, D. M., & O'Shea, J. J. (2016). Editorial: Decernotinib: A Next‐Generation Jakinib. Arthritis & Rheumatology. https://doi.org/10.1002/art.39463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.